ライフサイエンスコーパス: nonrandomized

1 r donors (47 of which were randomized and 53 nonrandomized).

2 10), single-group pretest/posttest (n = 2), nonrandomized 2-group (n = 13), and randomized clinical

3 One hundred forty nonrandomized, 6 randomized open-label, and 2 randomized

4 (ADAPT-DES) was a prospective, multicenter, nonrandomized "all-comers" study of 8583 consecutive pat

5 ty score analysis was used to adjust for the nonrandomized allocation of treatments.

6 In a post hoc, nonrandomized analysis from the FREEDOM (Future REvascul

7 Retrospective nonrandomized analysis is subject to residual confoundin

8 This large comprehensive nonrandomized analysis of longitudinal HRQL shows that T

9 We performed a nonrandomized analysis of survival/cardiovascular events

10 This is a post hoc, nonrandomized analysis of the completeness of revascular

11 patient data were used for a retrospective, nonrandomized analysis.

12 decision, EVT versus medical management, was nonrandomized and at the treating physicians' discretion

13 The selection was nonrandomized and nonprospectively collected.

14 There have been decades of nonrandomized and observational data available, but only

15 Initial, nonrandomized and uncontrolled studies show success rate

16 ratified by the type of study (randomized vs nonrandomized) and were significant only in randomized t

17 Inclusion criteria were all randomized, nonrandomized, and retrospective studies with data on SC

18 LECTION: Intervention studies (randomized or nonrandomized) assessing the efficacy of earplugs as a s

19 We included randomized and nonrandomized behavioral intervention and feeding studie

20 Patients were assigned in a nonrandomized but specified manner to receive treatment

21 This is a prospective, interventional, nonrandomized case series of patients undergoing office-

22 This was a nonrandomized chart review of eyes with subluxated intra

23 The aim of this prospective, nonrandomized clinical study is to evaluate the possible

24 Nonrandomized clinical study with historical controls.

25 Multicenter, retrospective, nonrandomized clinical study.

26 A nonrandomized clinical trial evaluating the LINKAGE inte

27 We conducted a nonrandomized clinical trial of 12 or 24 weeks of parita

28 Follow-up of a nonrandomized clinical trial to evaluate the 5-year anti

29 nical observer-blinded study (6 patients), 4 nonrandomized clinical trials (133 patients), 1 cohort s

30 have shown benefit in preclinical models and nonrandomized clinical trials.

31 ooled from 655 enrolled patients (135 from a nonrandomized cohort [n = 87 ipilimumab naive; n = 48 ip

32 Using a nonrandomized cohort of 742,909 non-emergent, isolated C

33 This was a retrospective, nonrandomized cohort study of patients who underwent a p

34 In this observational, nonrandomized cohort study, the 5-year DRFS for treated

35 Prospective nonrandomized cohort study.

36 ty of all surgically treated patients in the nonrandomized cohort was 30% (95% CI: 26%-35%) and 26% (

37 plus optimized background therapy on day 1 (nonrandomized cohort).

38 week of LT) were included in a retrospective nonrandomized cohort.

39 g 272 in the randomized cohort and 99 in the nonrandomized cohort.

40 randomized cohort and in 38% of those in the nonrandomized cohort; the mean increase in the CD4+ T-ce

41 In each of these countries, nonrandomized comparative clinical trials were initiated

42 We conducted a retrospective, nonrandomized comparative effectiveness study of dose-es

43 ature search identified randomized (RCT) and nonrandomized comparative observational clinical studies

44 Selection of high-quality, nonrandomized comparative studies (NRCTs) was based on a

45 Randomized and nonrandomized comparative studies that enrolled children

46 Seventeen randomized controlled trials and 3 nonrandomized comparative studies were included in this

47 nalyses, 26 randomized controlled trials, 11 nonrandomized comparative studies, 20 cohort studies, an

48 were randomized controlled trials, six were nonrandomized comparative studies, and 14 were single-ar

49 HCC and waiting for LT, there were only two nonrandomized comparative studies, both with a high risk

50 This is a retrospective, consecutive, nonrandomized comparative study of patients affected by

51 Retrospective, nonrandomized, comparative clinical study.

52 An observational, nonrandomized, comparative multicenter cohort study was

53 ction: Randomized, controlled trials (RCTs); nonrandomized, comparative studies (NRCSs); single-group

54 ials (RCTs) and prospective or retrospective nonrandomized, comparative studies of medical therapy al

55 In this nonrandomized, comparative study, 99 patients of various

56 Retrospective, nonrandomized, comparative study.

57 In a nonrandomized comparison of patients with clopidogrel lo

58 The study's main limitations include the nonrandomized comparison of vaccines from 2 different tr

59 In a single-center, prospective, nonrandomized comparison study, BRCA mutation carriers a

60 In a nonrandomized comparison within our trial center, we fou

61 Nonrandomized comparisons are liable to provide misleadi

62 Retrospective, nonrandomized, consecutive case series.

63 SETTING, AND PARTICIPANTS: A retrospective, nonrandomized, consecutive cohort study of a total of 20

64 the randomized controlled trial (n=574) and nonrandomized continued access (n=1358) cohorts were div

65 5 patients undergoing TA-TAVR in the PARTNER nonrandomized continued access (NRCA) registry and compa

66 nd mortality in these 2 arms and in the TAVR nonrandomized continued access (NRCA) registry cohort.

67 In the nonrandomized continued access cohort, there were no dif

68 randomized controlled trial cohort A and the nonrandomized continued access cohort.

69 of Aortic Transcatheter Valve) trial and the nonrandomized continued access registry.

70 A nonrandomized control cohort of LT patients were selecte

71 e review included 37 randomized trials and 2 nonrandomized controlled intervention studies (N = 65 88

72 Good- and fair-quality randomized and nonrandomized controlled intervention studies of behavio

73 udy designs were randomized clinical trials, nonrandomized controlled intervention studies, diagnosti

74 DESIGN, SETTING, AND PARTICIPANTS: Nonrandomized controlled intervention study conducted at

75 TTING, AND PARTICIPANTS: Multi-institutional nonrandomized controlled intervention study of 1068 chil

76 tic review with meta-analysis, randomized or nonrandomized controlled studies of conservative endomet

77 Small, nonrandomized controlled studies suggested benefit from

78 aintenance, a randomized controlled trial, a nonrandomized controlled trial, and an observational lon

79 ndomized controlled trials (n = 2554) and 11 nonrandomized controlled trials (n = 917) for inclusion

80 ception to May 2012 to locate randomized and nonrandomized controlled trials of patients receiving ac

81 c review and meta-analysis of randomized and nonrandomized controlled trials to determine whether wei

82 Nine randomized controlled trials and 13 nonrandomized controlled trials were selected from 216 r

83 y criteria: 1 randomized controlled trial, 4 nonrandomized controlled trials, 3 quasi-experimental tr

84 tations, including five randomized and seven nonrandomized controlled trials.

85 e Subjects study is an ongoing, prospective, nonrandomized, controlled intervention study conducted i

86 In a prospective, 3-center, nonrandomized, controlled study, 2 sequential groups of

87 Nonrandomized crossover trial involving 6 healthy adults

88 , we illustrate challenges involved in using nonrandomized data for this purpose with a case study fr

89 Nonrandomized data sources may inform the initial design

90 This nonrandomized data suggests no advantage for 4 mg over t

91 The largest body of randomized and nonrandomized data to date has been for the Watchman dev

92 These nonrandomized data were consistent with previous trials

93 as consolidative therapy is unclear in this nonrandomized data, but clearly warrants further study.

94 0th century because of conflicting and often nonrandomized data.

95 To reduce bias by residual confounding in nonrandomized database studies, the high-dimensional pro

96 rates were similar in a 1906-patient pooled nonrandomized DCB data set (Kaplan-Meier estimates of 2.

97 ovariates imposed by the program data, and a nonrandomized design limiting definitive ascertainment o

98 Potential limitations include its nonrandomized design that precludes causal inference, re

99 ese comparisons may be confounded due to the nonrandomized design.

100 elines, including prospective randomized and nonrandomized double-blind, single-blind, and open-label

101 We conducted nonrandomized effectiveness studies of ADT plus RT versu

102 The study sought a prospective multicenter nonrandomized evaluation of the Direct Flow Medical (DFM

103 MET and VEGFR2, was evaluated in a phase II nonrandomized expansion study in castration-resistant pr

104 bility Study) is a prospective, multicenter, nonrandomized feasibility study.

105 The multicenter, nonrandomized, first-in-human clinical CAPTURE (Carotid

106 cision makers often consider studies done in nonrandomized health care databases more difficult to re

107 including a propensity score, to adjust for nonrandomized ICD implantation after (123)I-mIBG.

108 Thirty-seven studies (32 randomized and 5 nonrandomized) including 4326 patients met inclusion cri

109 were observed between the randomized and the nonrandomized intervention groups.

110 ords to identify randomized clinical trials, nonrandomized intervention studies, and observational st

111 This prospective nonrandomized interventional cohort analysis performed a

112 A prospective nonrandomized interventional cohort study was conducted.

113 Prospective, crossover, nonrandomized interventional study.

114 Retrospective, nonrandomized, interventional case series.

115 We performed a prospective, multicenter, nonrandomized investigation evaluating the safety and ef

116 rmed a prospective, multicenter, controlled, nonrandomized investigation of self-expanding TAVR in pa

117 with a retrospective review of consecutive, nonrandomized, longitudinal case series of KPro implanta

118 In the pooled (randomized and nonrandomized) maintenance therapy population, histologi

119 gastroplasty (69%), or gastric bypass (12%); nonrandomized, matched, prospective controls received us

120 End-of-preschool follow-up of a nonrandomized, matched-group cohort of predominantly low

121 lity weighted (IPW) hazard ratios (HRs) in a nonrandomized Medicare-linked (age >/=65 years) patient

122 in the prospective, multicenter, open-label, nonrandomized ML-DS 2006 trial by Nordic Society for Ped

123 This prospective nonrandomized multicenter study was approved by the revi

124 In a prospective, nonrandomized multicenter trial, 45 eligible patients re

125 vascularized were enrolled in a prospective, nonrandomized, multicenter investigation testing percuta

126 This prospective, nonrandomized, multicenter trial included adult patients

127 ge recommendation, a phase I-II, open-label, nonrandomized, multicenter trial was therefore designed

128 should be interpreted cautiously, given the nonrandomized nature and the selection bias of the study

129 Because of the nonrandomized nature of this study, the indications for

130 Because of the nonrandomized nature of this study, these results should

131 We conducted a prospective nonrandomized, nonblinded, interventional study in 3 hos

132 2 clinical trial with a parallel, untreated, nonrandomized observational cohort of CSF biomarker-nega

133 llel, randomized clinical trial, including a nonrandomized observational group, conducted at 2 public

134 The HDF, Heart and Height study is a nonrandomized observational study comparing outcomes on

135 Materials and Methods This prospective, nonrandomized observational study included 1446 particip

136 ETHOD: This 5-year, prospective, open-label, nonrandomized, observational registry study was conducte

137 Prospective, nonrandomized, observational study.

138 In this phase 2, nonrandomized, open-label clinical trial conducted at th

139 Nonrandomized, open-label clinical trial initiated in 20

140 r 2 outcomes: (1) blood pressure changes for nonrandomized, open-label randomized, and blinded studie

141 In nonrandomized, open-label studies, a transcatheter inter

142 This phase 2, nonrandomized, open-label study evaluated brentuximab ve

143 We conducted a phase 3, nonrandomized, open-label study of the safety, efficacy,

144 This phase I, nonrandomized, open-label, dose-escalation (DE), and ext

145 We conducted a nonrandomized, open-label, multicenter, phase 4 study.

146 We conducted a nonrandomized, open-label, phase 2 clinical study evalua

147 METHODS AND A prospective, multicenter, nonrandomized, open-label, single-arm study of carotid a

148 This nonrandomized, parallel group, pharmacokinetic evaluatio

149 In this nonrandomized, parallel-cohort, phase 1b, multicenter st

150 s the therapeutic benefit of SNB in a large, nonrandomized patient cohort.

151 Of the nonrandomized patients in the observational study group,

152 Nonrandomized patients were followed in a prospective co

153 The VITAL study was an open-label nonrandomized phase 3 trial conducted to evaluate the ef

154 significantly from the 12-month score in the nonrandomized phase among the 23 participants in the the

155 KEYNOTE-012 was a multicenter, nonrandomized phase Ib trial of single-agent pembrolizum

156 Methods: Sixty-one patients treated in a nonrandomized phase II study (BRANCH) with concomitant o

157 ls, has shown promising clinical efficacy in nonrandomized phase II trials in patients with ovarian c

158 d in a National Cancer Institute open-label, nonrandomized, phase 2 clinical trial.

159 atment and household RUTF use.We conducted a nonrandomized pilot intervention study in which 115 chil

160 The results of this uncontrolled and nonrandomized pilot study suggest that the safety of rit

161 urope), a European prospective, multicenter, nonrandomized post-approval study of MitraClip therapy (

162 ve, randomized control trial with a parallel nonrandomized preference cohort and blinded endpoint of

163 In this nonrandomized prospective study, gray matter structure w

164 In a nonrandomized prospective trial, 168 patients who were a

165 Participants were from an ongoing, matched (nonrandomized) prospective intervention trial of the Swe

166 e Subjects (SOS) study, which was a matched (nonrandomized) prospective trial that compared bariatric

167 3 prospective, randomized clinical trials; 7 nonrandomized, prospective comparative studies; and 3 re

168 splant patients subjected to an independent, nonrandomized, prospective study of immunosuppression dr

169 sh Obese Subjects (SOS) study is an ongoing, nonrandomized, prospective, controlled study conducted a

170 In an analysis of data from a nonrandomized, prospective, controlled study, we examine

171 The nonrandomized, prospective, controlled Swedish Obese Sub

172 Nonrandomized publications were reviewed for the purpose

173 luded 32 studies (14 RCTs [n=109 763] and 18 nonrandomized quasi-experimental studies [n=54-423]).

174 n outcomes by study design comparing RCTs to nonrandomized quasi-experimental studies and by country

175 In contrast, nonrandomized quasi-experimental studies reported larger

176 Propensity scoring was used to account for nonrandomized referral to early revascularization (90 da

177 Transcatheter Valves) randomized trials and nonrandomized registries were studied.

178 Multicenter, nonrandomized registry of 1661 patients at intermediate

179 (n=542 patients) and those from a subsequent nonrandomized registry of patients undergoing Watchman i

180 ment consists largely of single institution, nonrandomized reports, limiting the ability to formulate

181 hd-PS is a flexible analytical tool for nonrandomized research across a range of study sizes and

182 A nonrandomized retrospective review.

183 In this nonrandomized, retrospective, comparative, single-center

184 detailed analysis of clinical outcomes in a nonrandomized setting is warranted.

185 ND PATIENTS: Multi-institutional, unblinded, nonrandomized single group phase 2 clinical trial to ass

186 alve US Expanded Use Study is a prospective, nonrandomized, single-arm study that evaluates safety an

187 Nonrandomized, single-blinded study using an interrupted

188 c cardiomyopathy have been limited to small, nonrandomized, single-center studies.

189 This Phase I, open-label, nonrandomized, single-sequence study assessed the effect

190 f the 1489 studies originally identified, 13 nonrandomized studies (0.9%) representing 25,950 patient

191 Based on 29 nonrandomized studies (3.701 patients) the model shows t

192 Meta-analysis of 11 nonrandomized studies (8858 patients) revealed that dela

193 Nonrandomized studies (NRSs) involving use of propensity

194 r comparing randomized controlled trials and nonrandomized studies (p = 0.25) and unchanged over time

195 n comparing randomized controlled trials and nonrandomized studies (p = 0.71), but decreased (p = 0.0

196 The meta-analysis included 11 nonrandomized studies and 5850 patients (1157 MV-PCI and

197 Nonrandomized studies and open-label randomized trials r

198 Nonrandomized studies are subject to residual confoundin

199 als, and EMBASE databases for randomized and nonrandomized studies comparing antibiotic therapy (AT)

200 We searched for randomized or nonrandomized studies comparing the effect of different

201 This analysis of both randomized and nonrandomized studies evaluating an antiangiogenic agent

202 from randomized controlled trials (RCTs) and nonrandomized studies for hospital-based acute coronary

203 Meta-analyses of nonrandomized studies have failed to demonstrate any sig

204 A total of 11 nonrandomized studies met the inclusion criteria, contri

205 Risk of Bias Assessment and Risk of Bias in Nonrandomized Studies of Interventions criteria for rand

206 Initially, 157 randomized and nonrandomized studies on therapies (systemic immunomodul

207 Randomized and nonrandomized studies reporting an intervention for colo

208 inception to 31 May 2014 for randomized and nonrandomized studies reporting seroconversions among un

209 Nonrandomized studies suggest that subvalvular repair is

210 The available evidence from mainly nonrandomized studies suggests that extended or continuo

211 This meta-analysis of nonrandomized studies suggests that in patients with car

212 There is evidence from nonrandomized studies that a proportion of ipilimumab-tr

213 and CENTRAL were searched for randomized and nonrandomized studies that compared iNPWT with control d

214 not consider a growing body of evidence from nonrandomized studies that provides insight into the eff

215 We identified 3 small randomized and 18 nonrandomized studies that reported 68 cases of endophth

216 other treatment options; no information from nonrandomized studies was available.

217 For nonrandomized studies we compared bleeding risk with oth

218 ion on health outcomes of adult outpatients; nonrandomized studies were eligible for harms.

219 Four randomized controlled trials and 22 nonrandomized studies were included.

220 enty-two randomized controlled trials and 71 nonrandomized studies were included.

221 these, 137 were randomized studies, 67 were nonrandomized studies with 2 or more groups, and 405 use

222 ysis (one randomized controlled trial; three nonrandomized studies with exposure limited to nighttime

223 randomized, controlled trials [RCTs] and 65 nonrandomized studies) met the inclusion criteria.

224 n a validated tool (Methodological Index for Nonrandomized Studies).

225 Twenty-one studies comprising 13 prospective nonrandomized studies, 1 prospective randomized, and 7 r

226 patients in 10 retrospective or prospective nonrandomized studies, 621 (34.4%) of whom were sedated.

227 a VT protocol was used postrandomization; in nonrandomized studies, baseline VT and PPlat.

228 From nonrandomized studies, cinacalcet appears to be safe and

229 udies, 4 randomized controlled trials, and 6 nonrandomized studies, which compared outcomes in heart

230 for analysis, including 7 randomized and 16 nonrandomized studies.

231 016 was conducted to identify randomized and nonrandomized studies.

232 67 randomized clinical trials (RCTs) and 11 nonrandomized studies.

233 of renal autonomic nerves has been proven in nonrandomized studies.

234 ers is critical for successful adjustment in nonrandomized studies.

235 ct items from the Newcastle-Ottawa Scale for nonrandomized studies.

236 C) is unclear, with conflicting results from nonrandomized studies.

237 lytic techniques can improve the accuracy of nonrandomized studies.

238 associated with poor neurological outcome in nonrandomized studies.

239 This prospective multicenter nonrandomized study (RESTAGE-HF [Remission from Stage D

240 study was a randomized controlled trial or a nonrandomized study and performed or not at an Acute Res

241 In a nonrandomized study at 13 centers in 11 countries, 187 p

242 This prospective nonrandomized study compared HRQL and survival after tho

243 We performed an open nonrandomized study comparing the immunological, virolog

244 s and Methods This was a prospective phase I nonrandomized study conducted between March 2013 and Oct

245 Nonrandomized study design and small sample of patients

246 Despite the small sample size and nonrandomized study design, these data suggest that a st

247 tients eligible to enroll in this open-label nonrandomized study either met on-treatment criteria for

248 Prospective, controlled, longitudinal, nonrandomized study enrolling 62 patients in 2 groups: A

249 yx ONE Clear was a prospective, multicenter, nonrandomized study evaluating the safety and effectiven

250 In this prospective, controlled, nonrandomized study involving 11 901 patients at 15 Mich

251 ure Patients) is a prospective, multicenter, nonrandomized study of 200 advanced heart failure patien

252 In this nonrandomized study of carefully selected patients under

253 We conducted a prospective, nonrandomized study of kidney transplantation in HIV-inf

254 This was a prospective, nonrandomized study of mature accesses that underwent ba

255 We performed a prospective, nonrandomized study to assess the safety of MRI at a mag

256 A multicenter, prospective, nonrandomized study was conducted of LAA closure with th

257 A prospective, multicenter, nonrandomized study was conducted.

258 Nonrandomized study with potential for unmeasured or res

259 Nonrandomized study with potential unmeasured confoundin

260 In a prospective nonrandomized study, a completely self-contained, single

261 rly approval of a new drug based on a robust nonrandomized study, buttressed by data from concurrent

262 this multicenter, international, two-cohort, nonrandomized study, we enrolled patients with metastati

263 Prospective, nonrandomized study.

264 mple concerns changes in hemoglobin A1c in a nonrandomized study.

265 A prospective, interventional, nonrandomized study.

266 clopidogrel or ticagrelor in a prespecified, nonrandomized subgroup analysis of the Platelet Inhibiti

267 n, we evaluated the effects of the drug in a nonrandomized subgroup.

268 ol subjects had hearing impairment, as did 1 nonrandomized subject.

269 In a nonrandomized subset of 165 infants (n=77 erythropoietin

270 he MRKAd5 HIV-1 vaccine, these findings in a nonrandomized subset of enrollees show an HLA-specific v

271 Post hoc analysis; examination of nonrandomized subsets of randomized groups after year 1.

272 n 40 +/- 8.7) was enrolled in a prospective, nonrandomized supplement study.

273 RI registry was established as an open-label nonrandomized surveillance databank without industry inv

274 , including a propensity score to adjust for nonrandomized treatment allocation.

275 core matching was used to minimize bias from nonrandomized treatment assignment.

276 ents (18.6%) were not enrolled but underwent nonrandomized treatment with the same DESs.

277 Participants who were prescribed any nonrandomized treatment without first meeting either det

278 Secondary analysis that included nonrandomized trial data.

279 A single-center, prospective, nonrandomized trial enrolled 100 consecutive PD for canc

280 , we performed a single-center, prospective, nonrandomized trial involving 36 patients with hematolog

281 ndomized controlled trials (837 patients), 7 nonrandomized trials (338 patients), and 41 noncontrolle

282 written about the epidemiological issues in nonrandomized trials aiming to evaluate the superiority

283 d trials for pulmonary infection and only in nonrandomized trials for mortality.

284 In patients with relapsed disease, data from nonrandomized trials have revealed promising responses,

285 herwise, national databases, registries, and nonrandomized trials were used.

286 effects remained significant after excluding nonrandomized trials, or trials of poor quality (Jadad s

287 (95% CI: 2.59, 7.12 nmol/L) was observed in nonrandomized trials.

288 as 0%-9% in randomized trials and 17%-23% in nonrandomized trials.

289 iciaries, we framed our study as a series of nonrandomized "trials" comparing vaccinated beneficiarie

290 ere enrolled in a prospective single-center, nonrandomized, unblinded investigation (Timing Based on

291 er were more likely to be smaller and to use nonrandomized, unblinded trial designs and surrogate end

292 We enrolled 47 patients in this open-label, nonrandomized, uncontrolled phase 2 study.

293 Open-label, nonrandomized, uncontrolled phase 3 trial conducted at 3

294 This open-label, nonrandomized, uncontrolled study consisted of a 24-week

295 We enrolled 12 patients in an open-label, nonrandomized, uncontrolled study of a single dose of ZF

296 In this open-label, nonrandomized, uncontrolled study, a high rate of SVR12

297 In this open-label, nonrandomized, uncontrolled study, patients with HIV who

298 Methods The prospective, nonrandomized UNCOVER AF trial (Utilizing Novel Dipole D

299 LIMITATION: Because this study was nonrandomized, unobserved differences may still exist be

300 ensity-matched analysis was adjusted for the nonrandomized use of the 2 strategies.